|Bid||266.82 x 800|
|Ask||266.90 x 800|
|Day's range||262.61 - 267.50|
|52-week range||229.40 - 277.29|
|Beta (5Y monthly)||0.61|
|PE ratio (TTM)||40.61|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||3.48 (1.32%)|
|Ex-dividend date||08 Sept 2022|
|1y target est||274.55|
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.83% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?